---
title: "CureVac BV (CVAC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CVAC.US.md"
symbol: "CVAC.US"
name: "CureVac BV"
industry: "Biotechnology"
datetime: "2026-05-20T10:34:54.801Z"
locales:
  - [en](https://longbridge.com/en/quote/CVAC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CVAC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CVAC.US.md)
---

# CureVac BV (CVAC.US)

## Company Overview

As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.66)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -86.69% |  |
| Net Profit YoY | 21.61% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 79025194.07 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | 182.11% | A |
| Gross Margin | 99.31% | A |
| Revenue YoY | -86.69% | E |
| Net Profit YoY | 21.61% | B |
| Total Assets YoY | 0.00% | D |
| Net Assets YoY | 0.00% | D |
| Cash Flow Margin | -93.26% | E |
| OCF YoY | -86.69% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 23.48% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - CureVac BV",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-86.69%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "21.61%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "79025194.07",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "182.11%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "99.31%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-86.69%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "21.61%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-93.26%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-86.69%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "23.48%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 7.29 | 10/386 | 7.29 | 6.38 | 5.66 |
| PB | 1.03 | 86/386 | 1.76 | 1.32 | 1.03 |
| PS (TTM) | 13.28 | 183/386 | 13.28 | 2.20 | 2.14 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-28T05:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 25% |
| Hold | 3 | 75% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.67 |
| Highest Target | 5.48 |
| Lowest Target | 4.98 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CVAC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CVAC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CVAC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CVAC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**